Ones To Watch News
Refine Search
Biotechnology
Epitopea, a UK and Canada-based cancer immunotherapeutics company, has partnered with nucleic acid delivery specialist Genevant Sciences to develop new RNA-based therapies targeting proprietary tumor antigens. 20 December 2024
Pharmaceutical
US biotech Assembly Biosciences has announced an equity investment of $20.1 million by Gilead Sciences to purchase additional common stock in the company and an amendment to their collaboration to advance the research and development of novel antiviral therapies with $10 million in accelerated funding. 20 December 2024
Pharmaceutical
Privately-held Xcovery Holdings, an oncology-focused pharma company, has announced that the US Food and Drug Administration (FDA) has approved Ensacove (ensartinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). 19 December 2024
Biotechnology
Privately-held biotech Ottimo Pharma today announces the completion of a Series A financing round of over $140 million. 19 December 2024
Biotechnology
Safi Biotherapeutics, a specialist in stem-cell derived red blood cell products, has received Rare Pediatric Disease designation and Orphan Drug designation from the US regulator. 19 December 2024
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Biotechnology
Danish diabetes care giant Novo Nordisk has entered into a definitive agreement to acquire Forma Therapeutics, a US clinical-stage biopharmaceutical company focused on transforming the lives of patients with sickle cell disease (SCD) and rare blood disorders, whose shares rocketed up 48% to $19.84 on the news. 19 September 2022
Biotechnology
Founded by Yale professors Akiko Iwasaki and Anna Marie Pyle, RIGImmune has announced its launch, an acquisition and a financing all in a single day. 15 September 2022
Biotechnology
Privately-held Swiss drug developer Neovii Pharmaceuticals has entered into an agreement with a unit of Shanghai Fosun Pharmaceutical, granting the latter an exclusive license to develop and commercialize Neovii's Grafalon (rabbit anti-human T-lymphocyte globulin, ATLG) in Chinese Mainland, Hong Kong SAR, Macau SAR and Taiwan region. 15 September 2022
Biotechnology
French start-up Tridek-One has closed a 16 million euros ($16.1 million) financing round. 15 September 2022
Biotechnology
Shares of Massachusetts, USA-based Rubius Therapeutics closed down 13% on Tuesday and fell a further 6% to $0.87 pre-market today, after it announced plans to restructure the company and align resources to advance its next generation red blood cell-based cell conjugation platform. 14 September 2022
Biotechnology
Acelyrin, a late-stage clinical biopharma company focused on accelerating the delivery of transformative medicines in immunology, has announced a $300 million Series C financing to fund izokibep Phase III development in psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA). 13 September 2022
Pharmaceutical
Israeli diabetes specialist Oramed Pharmaceuticals edged up 3% to $8.46 pre-market today, as it announced positive Phase II results from its double-blind, fully randomized, placebo-controlled, multicenter trial to assess the safety and efficacy of its oral insulin candidate (ORMD-0801), to reduce liver fat content in type 2 diabetes (T2D) patients with non-alcoholic steatohepatitis (NASH). 13 September 2022
Biotechnology
The value of Californian biotech Akero Therapeutics could double on Tuesday, with its shares already up by 89% in pre-market trading. 13 September 2022
Biotechnology
Yesterday, Nuvaxovid (NVX-CoV2373) COVID-19 vaccine was granted expanded conditional marketing authorization (CMA) in the European Union (EU) for use as a booster vaccine for adults aged 18 and older by the European Commission. 13 September 2022
Biotechnology
French biotech GenSight Biologics, which is developing gene therapy for rare and neurodegenerative diseases of the eye, is adding to its management team in anticipation of the European commercialization of Lumevoq (lenadogene nolparvovec). 13 September 2022
Biotechnology
California, USA-based biotech Allakos saw its share drop 12% in pre-market trading on Friday, as it reported mixed data from EoDyssey, a 24-week, Phase III randomized, double-blind, placebo-controlled study of lirentelimab in patients with biopsy confirmed eosinophilic duodenitis (EoD). However, the stock but more than recovered, closing up 5.7% at $4.90. 12 September 2022
Pharmaceutical
US biotech Revance Therapeutics closed trading 22% higher on Thursday. 9 September 2022
Pharmaceutical
French vaccines developer Valneva and USA-based VBI Vaccines today announced a partnership in select European markets for the marketing and distribution of PreHevbri [hepatitis B vaccine (recombinant, adsorbed)], the only 3-antigen hepatitis B vaccine approved in Europe. 8 September 2022
Pharmaceutical
Shares of Amylyx Pharmaceuticals rocketed up 74% in pre-market trading today on positive news from a regulatory advisory committee on its amyotrophic lateral sclerosis (ALS) drug candidate, having suffered earlier following the release of downbeat briefing papers from the US Food and Drug Administration’s (FDA) last Friday. 8 September 2022
Biotechnology
LifeArc revealed that its portfolio company Ducentis BioTherapeutics, a pre-clinical-stage UK biotechnology company focused on developing novel therapies for inflammation and autoimmune diseases, has been acquired by Arcutis Biotherapeutics. 8 September 2022
Biotechnology
Nodus Oncology has announced the completion of an asset purchase agreement (APA) for Basilea Pharmaceutica's novel poly (ADP-ribose) glycohydrolase (PARG) inhibitor discovery program. 8 September 2022
Biotechnology
Chinese biotech Hutchmed today announces summary results of the 691-patient, multi-regional clinical trial (MRCT) of fruquintinib. 8 September 2022
Biotechnology
California’s Arsenal Biosciences, a privately-held programmable cell therapy company engineering advanced CAR-T therapies for solid tumors, has closed a $220 million Series B financing. 7 September 2022
Biotechnology
US biotech Rhythm Pharmaceuticals yesterday announced that the European Commission (EC) has expanded the marketing authorization for Imcivree (setmelanotide) to include the treatment of obesity and control of hunger associated with genetically confirmed Bardet-Biedl syndrome (BBS) in adult and pediatric patients six years of age and older. 7 September 2022
Biosimilars
Germany-headquartered drugmaker Fresenius Kabi says that the US Food and Drug Administration (FDA) has approved its biosimilar, Stimufend (pegfilgrastim-fpgk), for use in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. 7 September 2022
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze